Harkness E, Macdonald W, Valderas J, Coventry P, Gask L, Bower P
FDA's 2026 GLP-1 Warnings: 990 Reports and What They Mean for JoinSkinny Patients FDA has published ongoing warnings about compounded GLP-1 products generally: Dosing errors from measuring doses out of multi-dose vials Use of salt forms (like semaglutide sodium) that haven't been proven safe or effective Adverse events, including hospitalization in some cases As of May 31, 2026: 990 adverse-event reports tied to compounded semaglutide, and more than 730 tied to compounded tirzepatide - FDA notes these reports may be incomplete and don't, by themselves, establish that a compounded drug caused the reported event On April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list - a move that would close the main legal pathway for large-scale outsourcing-facility compounding of these drugs absent a shortage, with a public comment period that ran through June 29, 2026 These are industry-wide regulatory developments, not findings against JoinSkinny or any specific pharmacy named in this article
For vitamin B12 pills, most people take these daily in doses recommended by their doc but taking 1,000 mcg daily is pretty standard
Key Points Homocysteine is associated with an increased risk of over 100 diseases or adverse outcomes which are listed at the end of this article, including almost all brain and mental health disorders, from childhood to old age, including dementia and Alzheimers In those with cardiovascular disease having a H score above 20 increases risk of death by almost five times, and every 5 point increase increases risk by a third
You can double check your coverage by consulting your Evidence of Coverage
